Today: 9 June 2026
Barclays share price in focus as £1 billion buyback starts after results jolt
11 February 2026
1 min read

Barclays share price in focus as £1 billion buyback starts after results jolt

London, Feb 11, 2026, 07:45 GMT — Premarket action.

  • Barclays finished Tuesday at 474.40 pence, dropping 2.5%.
  • After boosting its targets and laying out new capital returns, the bank kicked off a £1 billion share buyback.
  • The proposed cap on credit-card fees has U.S. card businesses under a microscope, with investors paying close attention.

Barclays shares drew attention again Wednesday. The British lender launched a fresh £1 billion share buyback, just a day after the stock slipped—even as the bank rolled out new targets and promised juicier payouts to shareholders.

Why does the set-up matter? Barclays is putting more weight on its U.S. business for growth, just as markets want to see evidence that European banks can still lift returns now that rate tailwinds are losing steam.

Barclays is drawing focus to its consumer and cards division alongside investment banking. The key issue: Are future returns hinging on execution rather than market cycles?

Barclays’ buyback kicks off Feb. 11, wrapping up by Aug. 10 at the latest. J.P. Morgan Securities is handling the on-market buys over at the London Stock Exchange—any shares picked up will be cancelled, the bank said.

Barclays on Tuesday posted a 12% rise in profit before tax for 2025, bringing the figure to 9.1 billion pounds. The bank is now aiming for a return on tangible equity above 14% by 2028, a target it laid out alongside earnings. Chief Executive C.S. Venkatakrishnan added that more than 15 billion pounds of capital will be handed back to shareholders between 2026 and 2028.

The plan rides largely on U.S. expansion, where rivals aren’t pulling punches. Finance director Anna Cross flagged the threat from a proposed 10% ceiling on credit card fees in Washington, noting Barclays has “a number of levers” to soften the impact—like managing costs and impairment charges.

Shares finished Tuesday at £4.74, slipping around 6% from the latest 52-week peak, with volume spiking to nearly 50 million shares—well above normal levels, according to data.

It’s been a bumpy stretch. The FTSE 100 slipped on Tuesday, while bank stocks saw uneven trading as investors juggled fresh earnings reports and broader economic jitters—Barclays dropped its numbers right in the thick of it.

Pay figures surfaced as well. Barclays reported Venkatakrishnan’s compensation for 2025 rose to 15 million pounds. The staff bonus pool went up 15%, reaching 2.2 billion pounds.

Barclays’ U.S. ADRs slipped roughly 2% to close at $26.16 in New York on Tuesday, pricing data showed.

Even so, risks linger. If regulators crack down harder on U.S. cards, fee income gets pinched. Investment banking? That’s tied to deal flow—one sharp turn and it’s a different picture. And those buybacks aren’t a given; they hinge on regulators signing off and the market holding up.

Looking ahead, UK banks keep earnings momentum going. NatWest is set to release results on Friday, offering fresh detail on margins, costs, and capital returns for the sector.

Stock Market Today

  • J.M. Smucker Shares Rise After Earnings Beat Despite Sales Warning
    June 9, 2026, 10:05 AM EDT. J.M. Smucker shares rose 3.16% in pre-market trading after the company reported a 20% rise in adjusted earnings per share to $2.77, beating Wall Street estimates. The packaged-food firm grew net sales by 6% to $2.27 billion in Q4 but issued a cautionary note, forecasting a 3-4% decline in annual sales for fiscal 2027, below analysts' expectations of 1% growth. CEO Mark Smucker highlighted a focus on organic volume growth and profit improvement amid shifts in industry pricing strategies. Coffee sales drove quarterly results with a 12% retail sales increase but volume declines. The company flagged risks including consumer shifts to store brands, weight-loss drug impacts, and tariff fluctuations. Smucker's outlook balances lower sales with improved profitability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
BAT share price slips again as buyback filing lands and Capital Group trims stake ahead of results
Previous Story

BAT share price slips again as buyback filing lands and Capital Group trims stake ahead of results

Legal & General share price slips as AI disruption worries keep UK insurers on edge
Next Story

Legal & General share price slips as AI disruption worries keep UK insurers on edge

Go toTop